This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Merck & Co., Inc.
Drug Names(s): Preminent, Losartan potassium and Hydrochlorothiazide, MK-954H (L50mg/H12.5mg), MK-0954A (L100mg/H12.5mg)
Historical drug revenue includes Hyzaar and Cozaar.
Hyzaar is a combination medication used in the treatment of high blood pressure. It combines losartan (Cozaar), an angiotensin II inhibitor, and hydrochlorothiazide, a diuretic that increases the output of urine, removing excess fluid from the body and thus lowering blood pressure.
Angiotensin II, the primary vasoactive hormone of the renin-angiotensin system, is a potent vasoconstrictor. It also stimulates aldosterone secretion by the adrenal cortex. Cozaar/Hyzaar blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor.
Deal Structure: Effective January 1991, Merck and E. I. du Pont de Nemours and Company (Du Pont) entered into a joint venture to form a worldwide pharmaceutical company for the research, marketing, manufacturing and sale of pharmaceutical and imaging agent products. Under separate agreements between Merck and Du Pont for which the joint venture carries out Du Pont's obligations, commencing in 1993 marketing applications were submitted worldwide for Cozaar and Hyzaar.
Partners: E. I. du Pont de Nemours and Company
Pink Sheet Avapro, Hyzaar Paragraph IV Filings
Additional information available to subscribers only: